Glenview Trust co grew its stake in shares of Johnson & Johnson (NYSE:JNJ – Free Report) by 0.3% during the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 155,915 shares of the company’s stock after purchasing an additional 499 shares during the quarter. Glenview Trust co’s holdings in Johnson & Johnson were worth $24,167,000 at the end of the most recent quarter.
A number of other hedge funds and other institutional investors also recently modified their holdings of JNJ. GW&K Investment Management LLC acquired a new position in shares of Johnson & Johnson during the fourth quarter worth about $35,000. Dark Forest Capital Management LP lifted its stake in shares of Johnson & Johnson by 1,044.4% in the fourth quarter. Dark Forest Capital Management LP now owns 206 shares of the company’s stock worth $36,000 after acquiring an additional 188 shares in the last quarter. Ruedi Wealth Management Inc. acquired a new position in shares of Johnson & Johnson in the fourth quarter worth about $42,000. Kepos Capital LP acquired a new position in shares of Johnson & Johnson in the fourth quarter worth about $45,000. Finally, FWL Investment Management LLC acquired a new position in shares of Johnson & Johnson in the fourth quarter worth about $114,000. Institutional investors and hedge funds own 67.57% of the company’s stock.
Insiders Place Their Bets
In other Johnson & Johnson news, insider William Hait sold 14,698 shares of the company’s stock in a transaction that occurred on Wednesday, July 26th. The stock was sold at an average price of $172.00, for a total value of $2,528,056.00. Following the completion of the sale, the insider now directly owns 87,747 shares in the company, valued at $15,092,484. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. In other Johnson & Johnson news, VP Peter Fasolo sold 20,000 shares of the company’s stock in a transaction that occurred on Tuesday, July 25th. The stock was sold at an average price of $170.32, for a total value of $3,406,400.00. Following the completion of the sale, the vice president now directly owns 102,696 shares in the company, valued at $17,491,182.72. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider William Hait sold 14,698 shares of the stock in a transaction on Wednesday, July 26th. The shares were sold at an average price of $172.00, for a total value of $2,528,056.00. Following the sale, the insider now owns 87,747 shares of the company’s stock, valued at approximately $15,092,484. The disclosure for this sale can be found here. Insiders sold 47,163 shares of company stock worth $7,928,856 over the last ninety days. Company insiders own 0.20% of the company’s stock.
Analysts Set New Price Targets
Check Out Our Latest Report on Johnson & Johnson
Johnson & Johnson Stock Performance
Shares of JNJ stock opened at $172.55 on Friday. Johnson & Johnson has a 12-month low of $150.11 and a 12-month high of $181.04. The firm has a market capitalization of $448.45 billion, a price-to-earnings ratio of 34.93, a price-to-earnings-growth ratio of 2.89 and a beta of 0.54. The business has a 50 day simple moving average of $166.30 and a 200 day simple moving average of $161.44. The company has a debt-to-equity ratio of 0.44, a current ratio of 1.12 and a quick ratio of 0.88.
Johnson & Johnson (NYSE:JNJ – Get Free Report) last issued its quarterly earnings data on Thursday, July 20th. The company reported $2.80 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.62 by $0.18. Johnson & Johnson had a return on equity of 36.72% and a net margin of 13.35%. The business had revenue of $25.53 billion during the quarter, compared to analyst estimates of $24.63 billion. During the same period in the prior year, the company posted $2.59 EPS. The business’s revenue for the quarter was up 6.3% compared to the same quarter last year. On average, equities research analysts anticipate that Johnson & Johnson will post 10.75 EPS for the current year.
Johnson & Johnson Announces Dividend
The company also recently announced a quarterly dividend, which will be paid on Thursday, September 7th. Shareholders of record on Monday, August 28th will be given a $1.19 dividend. The ex-dividend date of this dividend is Friday, August 25th. This represents a $4.76 dividend on an annualized basis and a yield of 2.76%. Johnson & Johnson’s dividend payout ratio (DPR) is 96.36%.
Johnson & Johnson Company Profile
Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment provides skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; TYLENOL acetaminophen products; SUDAFED cold, flu, and allergy products; BENADRYL and ZYRTEC allergy products; MOTRIN IB ibuprofen products; NICORETTE smoking cessation products; and PEPCID acid reflux products.
Featured Stories
- Five stocks we like better than Johnson & Johnson
- 3 Small Caps With Big Return Potential
- 8 Best Artificial Intelligence Stocks Under $10
- Stock Trading Terms – Stock Terms Every Investor Needs to Know
- What Ross Stores Earnings Say About The Saver Shopping Economy
- How to Read Stock Charts for Beginners
- 6 Largest Healthcare REITs to Buy and How to Invest
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.
